Abdominal Pain in Inflammatory Bowel Diseases: A Clinical Challenge
- PMID: 35893357
- PMCID: PMC9331632
- DOI: 10.3390/jcm11154269
Abdominal Pain in Inflammatory Bowel Diseases: A Clinical Challenge
Abstract
Up to 60% of inflammatory bowel disease (IBD) patients experience abdominal pain in their lifetime regardless of disease activity. Pain negatively affects different areas of daily life and particularly impacts the quality of life of IBD patients. This review provides a comprehensive overview of the multifactorial etiology implicated in the chronic abdominal pain of IBD patients including peripheral sensitization by inflammation, coexistent irritable bowel syndrome, visceral hypersensitivity, alteration of the brain-gut axis, and the multiple factors contributing to pain persistence. Despite the optimal management of intestinal inflammation, chronic abdominal pain can persist, and pharmacological and non-pharmacological approaches are necessary. Integrating psychological support in care models in IBD could decrease disease burden and health care costs. Consequently, a multidisciplinary approach similar to that used for other chronic pain conditions should be recommended.
Keywords: abdominal pain; inflammatory bowel disease; quality of life.
Conflict of interest statement
P.W. declares no conflict of interest. B.C. declares no conflict of interest. F.D. declares no conflict of interest. S.D. has served as a speaker, consultant, and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma, and Vifor. L.P.-B. declares personal fees from Galapagos, AbbVie, Janssen, Genentech, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Allergan, MSD, Roche, Arena, Gilead, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, Thermo Fisher; grants from Abbvie, MSD, Takeda, and Fresenius Kabi; stock options: CTMA.
Figures


Similar articles
-
Pain management in patients with inflammatory bowel disease: insights for the clinician.Therap Adv Gastroenterol. 2012 Sep;5(5):339-57. doi: 10.1177/1756283X12446158. Therap Adv Gastroenterol. 2012. PMID: 22973418 Free PMC article.
-
Neuroanatomy of lower gastrointestinal pain disorders.World J Gastroenterol. 2014 Jan 28;20(4):1005-20. doi: 10.3748/wjg.v20.i4.1005. World J Gastroenterol. 2014. PMID: 24574773 Free PMC article. Review.
-
A Review of Inflammatory Bowel Disease: A Model of Microbial, Immune and Neuropsychological Integration.Public Health Rev. 2021 May 5;42:1603990. doi: 10.3389/phrs.2021.1603990. eCollection 2021. Public Health Rev. 2021. PMID: 34692176 Free PMC article. Review.
-
The Impact of Inflammatory Bowel Disease in Canada 2018: Quality of Life.J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S42-S48. doi: 10.1093/jcag/gwy048. Epub 2018 Nov 2. J Can Assoc Gastroenterol. 2019. PMID: 31294384 Free PMC article.
-
Pain management in patients with inflammatory bowel disease: translational approaches from bench to bedside.Inflamm Bowel Dis. 2014 Dec;20(12):2433-49. doi: 10.1097/MIB.0000000000000170. Inflamm Bowel Dis. 2014. PMID: 25208108 Review.
Cited by
-
Distinct Alterations in Central Pain Processing of Visceral and Somatic Pain in Quiescent Ulcerative Colitis Compared to Irritable Bowel Syndrome and Health.J Crohns Colitis. 2023 Nov 8;17(10):1639-1651. doi: 10.1093/ecco-jcc/jjad080. J Crohns Colitis. 2023. PMID: 37161902 Free PMC article.
-
Disease-specific alterations in central fear network engagement during acquisition and extinction of conditioned interoceptive fear in inflammatory bowel disease.Mol Psychiatry. 2024 Nov;29(11):3527-3536. doi: 10.1038/s41380-024-02612-7. Epub 2024 May 27. Mol Psychiatry. 2024. PMID: 38802508 Free PMC article.
-
Abdominal Pain in Inflammatory Bowel Disease-Epidemiology, Pathophysiology, and Management: A Narrative Review.Pain Ther. 2024 Dec;13(6):1447-1469. doi: 10.1007/s40122-024-00672-9. Epub 2024 Oct 28. Pain Ther. 2024. PMID: 39466554 Free PMC article. Review.
-
Dorsal root ganglion stimulation provides functional improvement from debilitating abdominal pain in Crohn's disease: A 12-month follow-up.Interv Pain Med. 2024 Dec 2;3(4):100524. doi: 10.1016/j.inpm.2024.100524. eCollection 2024 Dec. Interv Pain Med. 2024. PMID: 39697857 Free PMC article.
-
Does Magnesium Provide a Protective Effect in Crohn's Disease Remission? A Systematic Review of the Literature.Nutrients. 2024 May 28;16(11):1662. doi: 10.3390/nu16111662. Nutrients. 2024. PMID: 38892595 Free PMC article.
References
-
- Khanna R., Zou G., D’Haens G., Feagan B.G., Sandborn W.J., Vandervoort M.K., Rolleri R.L., Bortey E., Paterson C., Forbes W.P., et al. A Retrospective Analysis: The Development of Patient Reported Outcome Measures for the Assessment of Crohn’s Disease Activity. Aliment. Pharmacol. Ther. 2015;41:77–86. doi: 10.1111/apt.13001. - DOI - PubMed
-
- Turner D., Ricciuto A., Lewis A., D’Amico F., Dhaliwal J., Griffiths A.M., Bettenworth D., Sandborn W.J., Sands B.E., Reinisch W., et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target Strategies in IBD. Gastroenterology. 2021;160:1570–1583. doi: 10.1053/j.gastro.2020.12.031. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources